Meeting
2022 ASCO Quality Care Symposium
Association between oncology clinical pathway utilization and quality and cost outcomes in patients with metastatic solid tumors.
Authors
Ying Liu
Anthem, Inc., Wilmington, DE
Ying Liu, Samyukta Mullangi, Xiaoxue Chen, Timothy Pham, David Joseph Debono, Michael Jordan Fisch, Aliza Gordon, Dawn L. Hershman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Palliative and Supportive Care,Technology and Innovation in Quality of Care,Quality, Safety, and Implementation Science
Sub Track
Use of Clinical Pathways
Citation
J Clin Oncol 40, 2022 (suppl 28; abstr 430)
DOI
10.1200/JCO.2022.40.28_suppl.430
Abstract #
430
Poster Bd #
G3
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
CBX-12-101: A first-in-human study of CBX-12, an alphalex peptide drug conjugate (PDC) in patients (pts) with advanced or metastatic solid tumors.
First Author: Ildefonso I Rodriguez Rivera
Poster
2020 ASCO Virtual Scientific Program
A phase I/II study of GB1275, a first-in-class oral CD11b modulator, alone, and combined with pembrolizumab in specified advanced solid tumors or with chemotherapy in metastatic pancreatic cancer (KEYNOTE-A36).
First Author: Drew W. Rasco
Poster
2014 Gastrointestinal Cancers Symposium
Cost differential among systemic therapies for colon cancer.
First Author: Hasan Nadeem
Poster
2024 ASCO Annual Meeting
Systemic anti-cancer therapy and cost at end of life: A SEER Medicare analysis.
First Author: Kerin B. Adelson